Could oral rivaroxaban replace fondaparinux injections for superficial vein thrombosis? This 2017 appraisal of SURPRISE examines its non-inferiority design, composite outcomes, bleeding and generalisability, asking how convenience should be weighed against uncertainty about benefits and harms.
The rise and SURPRISE of the DOACs. St.Emlyn’s Read More
Does low-molecular-weight heparin prevent symptomatic clots after lower-limb casting? This 2016 review of POT-CAST examines a trial that found no statistically significant reduction, while discussing patient selection, low event numbers and the unresolved question of benefit in higher-risk groups.
JC: Clots in Pots gets Top Spot. Thromboprophylaxis at St.Emlyn’s Read More
What are the thromboembolic risks when prothrombin complex concentrate is used to reverse warfarin-associated intracranial bleeding? This 2015 appraisal examines a retrospective study, the importance of previous venous thromboembolism and the limitations of drawing conclusions from a different reversal regimen and clinical setting.
Nil nocere: do no harm reversing warfarin! Read More
Dan Horner’s 2015 RCEM masterclass asks how clinicians can investigate suspected venous thromboembolism without unnecessary testing or treatment. It explores pre-test probability, diagnostic tools and their limitations, then considers individual risks, patient preferences and the need to assess new approaches within local practice.
VTE masterclass with Dan Horner at #RCEM15 Read More
Should abdominal and pelvic CT be added to cancer screening after an unprovoked venous thromboembolism? This 2015 appraisal examines a Canadian randomised trial, missed cancers during follow-up and the limits of applying results from specialist clinics to other settings.
JC: Do all VTE patients need a CT for cancer? Read More
Rick Body and Kerstin de Wit introduce the drugs then known as novel oral anticoagulants in this 2015 podcast. The first part explores how they work, their place alongside older treatments, prescribing considerations and monitoring, capturing the questions surrounding their early adoption in emergency practice.
Get the NOAC Knowhow: Novel Oral Anticoagulants Part 1 Read More
How impressive are relative reductions in bleeding when the absolute event rates are small? This 2012 appraisal of newer oral anticoagulants for venous thromboembolism examines a systematic review, the comparison with warfarin and concerns at the time about managing major bleeding.
The new oral anticoagulants – the good news – or is it? Read More
Who needs thromboprophylaxis after lower-limb immobilisation? This 2012 discussion introduces College of Emergency Medicine guidance, considers the evidence for ambulatory trauma patients and argues for individual VTE risk assessment rather than treating every plaster cast in the same way.
The POP, the Chief, his risk assessment and her thromboprophylaxis Read More
